UI Hospitals and Clinics

Clinical Trial Details

Short Title
Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer
Official Title

A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer

Description

Participants in this research study have been diagnosed with breast cancer. The purpose of this research study is to test the effectiveness of a drug called Vandetanib on tumor growth markers. Vandetanib is currently used to treat a specific, rare type thyroid cancer. It is not approved for use in breast cancer so its use in this study is considered experimental. Previous research suggests that it may have anti-breast cancer activity. Approximately 80 people will take part in this study conducted by investigators at the University of Iowa.

Start Date
September 26, 2013
End Date
January 17, 2016
Gender Preference
Female
Age Group
18 - 99 years
Principal Investigator
Ronald Weigel, MD, PhD
Contact Info

Michelle Arnold, (319) 356-2778

Department
Surgery
Keywords
201301763 ; Breast cancer ; cancer ; phase two ; Weigel ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.